Anti-Clotting Drug Apixaban Receives NICE Approval

British drug regulator National Institute for Health and Clinical Excellence (NICE) has approved the use of the anti-clotting drug manufactured by Pfizer and Bristol-Meyers, apixaban, in preventing blood clots post hip and knee surgery.

NICE said that apixaban, which is being marketed under the brand name Eliquis, was a cost effective and clinically effective option in treating blood clots.

The treatment for knee replacement patients will last for 12 days and will cost around �41.16 while it will last for 34 days for hip replacement patients and will cost �116.62.




Source: Medindia